CONHIV14 - Treatment Strategies – Part one - page 1

P233 Tolerability is more important than simplicity for treatment durability
Trottier, B*; Machouf, N; Huchet, E; Lavoie, S; Vezina, S; Boissonnault, M; Charest, L; Munoz, M; Legault, D; Longpré, D; Thomas,
R; (Montreal, Canada)
P234 Can we trust the guidelines? Comparison between the data presented and the recommendations of the International
Antiviral Society-USA Panel
Piso, R* (Olten, Switzerland)
P236 Treatment modification in HIV-Infected individuals starting antiretroviral therapy between 2011 and 2014
Rappold, M*; Rieger, A; Steuer, A; Geit, M; Sarcletti, M; Haas, B; Taylor, N; Kanatschnig, M; Leierer, G; Ledergerber, B; Zangerle, R
(Innsbruck, Austria)
P237 Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data
from the ICONA cohort
Saracino, A*; Lorenzini, P; Lo Caputo, S; Girardi, E; Castelli, F; Bonfanti, P; Galli, M; Caramello, P; Abrescia, N; Mussini, C; Monno,
L; d’Arminio Monforte, A (Bari, Italy)
P238 144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the
German STAR/STELLA cohort
Wolf, E*; Trein, A; Baumgarten, A; Stephan, C; Jaeger, H; Hillenbrand, H; Koeppe, S; Lutz, T; Koenig, B; Stellbrink, H (Munich,
Germany)
P239 An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in
HIV-infected patients in Italy
Cozzi-Lepri, A*; Antinori, A; Bonora, S; Cingolani, A; Cassola, G; Angarano, G; Vullo, V; Mussini, C; Gori, A; Maggiolo, F; Castagna, A;
d’Arminio Monforte, A; on behalf of the ICONA Foundation (London, UK)
P240 Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected
treatment-naïve adults
Tashima, K*; Crofoot, G; Tomaka, F; Kakuda, T; Brochot, A; Vanveggel, S; Opsomer, M; Garner, W; Margot, N; Custodio, J; Fordyce,
M; Szwarcberg, J (Providence, USA)
P241 Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicenter cohort of HIV-infected
ARV-naïve patients
Podzamczer, D*; Rojas, J; Neves, I; Ferrer, E; Llibre, J; Leal, M; Gorgolas, M; Crusells, M; Gatell, J; Correia Abreu, R; Curto, J;
Domingo, P; Barrufet, M; Rozas, N (Barcelona, Spain)
P242 Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral
load.
Sterrantino, G*; Zaccarelli, M; Prati, F; Boschi, A; Sighinolfi, L; Borghi, V (Florence, Italy)
P243 Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons
receiving care in Italy
Cozzi-Lepri, A*; Lo Caputo, S; Maggiolo, F; Antinori, A; Ammassari, A; Marchetti, G; Mastroianni, C;
Gori, A; Di Perri, G; Angarano, G; Carbone, A; d’Arminio Monforte, A; on behalf of the ICONA Foundation Study (London, UK)
P244 Long-term effect of a four-drugs induction regimen for patients with high baseline viral load
Maggiolo, F*; Masini, G; Astuti, N; Di Filippo, E; Benatti, S; Valenti, D; Callegaro, A; Rizzi, M (Bergamo, Italy)
P245 Who gets single tablet regimens (STR), and why?
Tarrier, L; Kegg, S* (London, UK)
P246 Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHI
Bottani, G; Oreni, M; Orofino, G; Tau, P; Di Nardo Stuppino, S; Colella, E; Carosella, S; Guastavigna, M; Ghisetti, V; Micheli, V; Galli, M;
Rusconi, S* (Milan, Italy)
P247 An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir +
abacavir/lamivudine
Rogatto, F*; Bouee, S; Jeanbat, V; Piontkowsky, D; Aragao, F; Bosse, M (Uxbridge, UK)
P248 Efficacy and tolerability of Etravirine in HIV-1 adults patients: Results of a large French prospective cohort
Allavena, C*; Katlama, C; Cotte, L; Roger, P; Delobel, P; Cheret, A; Duvivier, C; Poizot-Martin, I; Hoen, B; Cabié, A; Cheret, A;
Lahoulou, R; Raffi, F; Pugliese, P (Nantes, France)
P249 Impact of etravirine use on hospitalization rates among highly pre-treated failing HIV-1 infected individuals between 2005
and 2011
Lacombe, J; Goujard, C; Valantin, M; Cheret, A; Lahoulou, R; Girard, P; Costagliola, D* (Paris, France)
TREATMENT STRATEGIES
– PART ONE
*Indicates presenting author.
1 2,3,4,5,6,7,8,9,10,11,...17
Powered by FlippingBook